Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Takuya, Ebihara"'
Publikováno v:
Polymer Journal. 53:121-127
Terpolymerization of carbon dioxide (CO2), propylene oxide (PO), and epoxide with bulky side groups (styrene oxide (SO), cyclohexylethylene oxide (CyEO), tert-butylethylene oxide (tBuEO), or 1-adamantylethylene oxide (AdEO)) was conducted by using a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d931863690ab7d4679b78ce4ffebf476
https://doi.org/10.1038/s41428-020-00412-8
https://doi.org/10.1038/s41428-020-00412-8
Autor:
Takuya Ebihara1 takuya.ebihara@axcelead-ddp.com, Hisao Shimizu1, Masami Yamamoto1, Tomoaki Higuchi1, Fumihiro Jinno1, Yoshihiko Tagawa1
Publikováno v:
Xenobiotica. May2019, Vol. 49 Issue 5, p584-590. 7p.
Autor:
Tomoaki Higuchi, Takuya Ebihara, Masami Yamamoto, Fumihiro Jinno, Hisao Shimizu, Yoshihiko Tagawa
Publikováno v:
Xenobiotica. 49:584-590
The pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, was investigated in rats with subcutaneously injected turpentine oil, which was an inflammation animal model. Following intravenous administration of TAK-272 to the turpenti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8edafe840e1dfadd5f1b0c9cc33d7b2
https://doi.org/10.1080/00498254.2018.1480817
https://doi.org/10.1080/00498254.2018.1480817
Publikováno v:
Biopharmaceutics & Drug Disposition. 39:175-183
In the search for orally available drugs, the prediction of human pharmacokinetics (PK) is essential for successfully selecting compounds that will be clinically useful. This report describes the selection of TAK-272 (SCO-272), a novel orally active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8586da206cabc109969d5e1e456e9597
https://doi.org/10.1002/bdd.2124
https://doi.org/10.1002/bdd.2124
Autor:
Martin Paton, Mingxiang Liao, Patrick Kirby, Shaoxia Yu, Takuya Ebihara, Francis S. Wolenski, Andy Z. X. Zhu, Yvonne P. Dragan, Majid Vakilynejad, Christopher Gemski, Swapan Chowdhury, Jessica L. Grieves, Vilmos Csizmadia, Liping Pan, Yuu Moriya, Mike Johnson
Publikováno v:
Toxicological Sciences
Fasiglifam (TAK-875), a Free Fatty Acid Receptor 1 (FFAR1) agonist in development for the treatment of type 2 diabetes, was voluntarily terminated in phase 3 due to adverse liver effects. A mechanistic investigation described in this manuscript focus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef2d7dea0c797e1eeb551fd9505608aa
http://europepmc.org/articles/PMC5414857
http://europepmc.org/articles/PMC5414857
Autor:
Yoshihiko Tagawa, Takuya Ebihara, Leslie Z. Benet, Akifumi Kogame, Ikuo Mori, Akio Morohashi, Yuu Moriya, Liping Pan, Hideo Fukui
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 47(5)
Fasiglifam, a potent and highly selective agonist of G protein-coupled receptor 40, was developed for the treatment of type 2 diabetes mellitus. However, phase III clinical programs were terminated owing to liver safety concerns. Fasiglifam-related l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c785acd21acad942d05460933981799
https://pubmed.ncbi.nlm.nih.gov/30765394
https://pubmed.ncbi.nlm.nih.gov/30765394
Autor:
Takuya, Ebihara, Hisao, Shimizu, Masami, Yamamoto, Tomoaki, Higuchi, Fumihiro, Jinno, Yoshihiko, Tagawa
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 49(5)
The pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, was investigated in rats with subcutaneously injected turpentine oil, which was an inflammation animal model. Following intravenous administration of TAK-272 to the turpenti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b7d0a1360ba56859155d3a162514ea51
https://pubmed.ncbi.nlm.nih.gov/29790816
https://pubmed.ncbi.nlm.nih.gov/29790816
Publikováno v:
Biopharmaceuticsdrug disposition. 39(3)
In the search for orally available drugs, the prediction of human pharmacokinetics (PK) is essential for successfully selecting compounds that will be clinically useful. This report describes the selection of TAK-272 (SCO-272), a novel orally active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::52a6fc1bf3414c2cf712feefb40de195
https://pubmed.ncbi.nlm.nih.gov/29474740
https://pubmed.ncbi.nlm.nih.gov/29474740
Autor:
Toshiyuki Takeuchi, Yoshihiko Tagawa, Takuya Ebihara, Rie Kadotani, Takahiro Kondo, Fumihiro Jinno, Yuu Moriya, Tomoo Itoh, Satoru Asahi
Publikováno v:
Biopharmaceutics & Drug Disposition. 34:236-246
Previous studies on the metabolic fate of resatorvid (TAK-242) have shown that species differences in the pharmacokinetics of 4-amino-3-chlorophenyl hydrogen sulfate (M-III), a metabolite of TAK-242, between rats and dogs are mainly attributable to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68ad620759cbd643534a5c4e88ac004c
https://doi.org/10.1002/bdd.1841
https://doi.org/10.1002/bdd.1841
Autor:
Satoru Asahi, Takuya Ebihara, Yoshihiko Tagawa, Yuu Moriya, Takahiro Kondo, Toshiyuki Takeuchi, Toshiya Moriwaki
Publikováno v:
Drug research. 66(6)
TAK-475 (lapaquistat acetate) is a squalene synthase inhibitor and M-I is a pharmacologically active metabolite of TAK-475. Preclinical pharmacokinetic studies have demonstrated that most of the dosed TAK-475 was hydrolyzed to M-I during the absorpti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ac747c175b1454b753ea3b44ad7f1c8
https://pubmed.ncbi.nlm.nih.gov/27011383
https://pubmed.ncbi.nlm.nih.gov/27011383